CNS Pharmaceuticals (CNSP) Stock Statistics & Valuation Metrics

CNS Pharmaceuticals has a market cap or net worth of $3.85M. The enterprise value is -$4.80M.

CNS Pharmaceuticals has 620,290 shares outstanding. The number of shares has decreased by -2.65% in one year.

CNS Pharmaceuticals’s return on equity (ROE) is -2.41 and return on invested capital (ROIC) is -229.17%.

The current PE Ratio of CNS Pharmaceuticals is ―. CNS Pharmaceuticals’s PEG ratio is 0.04.

In the last 12 months, CNS Pharmaceuticals had revenue of 0.00 and earned -14.86M in profits. Earnings per share was -38.87.

In the last 12 months, operating cash flow was -16.23M and capital expenditures -4.19K, giving a free cash flow of -16.23M billion.

CNS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CNS Pharmaceuticals upcoming earnings date is May 18, 2026, After Close (Confirmed).

CNS Pharmaceuticals as a current ratio of 3.43, with Debt / Equity ratio of 0.31%

In the past 12 months, CNS Pharmaceuticals has paid 0.00 in taxes.

CNS Pharmaceuticals EV to EBITDA ratio is -1.13, with an EV/FCF ratio of -0.98.

CNS Pharmaceuticals has $9.86M in cash and marketable securities with $30.79K in debt, giving a net cash position of $9.83M billion.

Gross margin is -20.10%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for CNS Pharmaceuticals is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy